CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…
CHICAGO—Stem cell transplantation for systemic sclerosis patients has come a long way over the past decade, with more finely calibrated dosing and better patient selection, said George Georges, MD, associate member of the Fred Hutchinson Cancer Research Center and associate professor in the medical oncology division at the University of Washington School of Medicine, Seattle,…
CHICAGO—Scleroderma patients with pulmonary arterial hypertension (PAH) might benefit from more aggressive therapy, an expert in the field said in a session on lung involvement in rheumatic diseases at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May. Newer trials—the SERAPHIN trial on macitentan, GRIPHON on selexipag, and AMBITION on an ambrisentan/tadalafil combination—show…
CHICAGO—David Daikh, MD, PhD, professor of medicine at the University of California San Francisco and chief of the Rheumatology Division at the San Francisco VA Medical Center, said the overlap between malignant disease and rheumatic disease means rheumatologists should stay aware that more may be going on than just a rheumatic disorder. He made his…
The annual ACR State-of-the-Art (SOTA) Clinical Symposium came highly endorsed by previous fellows; therefore, upon receiving the invitation for the Fellows-in-Training (FIT) scholarship, I did not hesitate to apply. Further, the meeting was going to be held in the spring in Chi Town! Meticulously, I made arrangements with six hundred scholarship dollars at my disposal….
ACR’s education and networking seminar to address latest in research, therapy, and scientific advances in rheumatology
Clinical excellence is the foundation of a successful practice. Advancing the integration of evidence-based science and clinical expertise, the State-of-the-Art Clinical Symposium leads the way for rheumatologists to enhance their professional effectiveness and improve their patients’ outcomes.
Clinical updates from the ACR Symposium
Join the ACR in Chicago April 13–15 for the 2007 State-of-the-Art Clinical Symposium. The symposium will start with a focus on lupus with presentations on pathophysiology, trial metrics, and a review of recently completed clinical trials. Saturday afternoon will include an update on several diseases including Sjögren’s syndrome, fibromyalgia, pediatric vasculitis, and myositis. Following RA presentations Sunday morning, the symposium will conclude with the always-popular “Year in Review” presentation.